Gynecological Cancer Drugs Market 2020: In-Depth Analysis, Applications, Key End-Users Forecasts To 2028

Gynecological Cancer Drugs
Gynecological Cancer Drugs

Gynecological Cancer Drugs are defined as the uncontrollable growth and spread of abnormal cells in the female reproductive organs, including the cervix, uterus, ovaries, vagina, and vulva. Furthermore, one of the risk factors for gynaecological cancer is infection with the virus known as HPV, or Human Papillomavirus. Furthermore, factors such as infertility, obesity, mutations, early menstruation or late menopause can all lead to gynaecological cancer.

To meet the growing Demand For Gynecological Cancer Drugs, pharmaceutical and biotech companies are focusing on research and development in order to bring new gynecological cancer drugs to market. Furthermore, some generic drug manufacturers are focusing on producing patent-expired drugs in generic form for the treatment of this cancer. 

For example, Dr Reddy's Laboratories, based in India, received US Food and Drug Administration approval in May 2017 to market Doxorubicin Hydrochloride Liposome injection in the United States. This Doxorubicin Hydrochloride Liposome is a therapeutic equivalent generic version of Doxil, a chemotherapy drug used to treat cancers like ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma.

The rising prevalence of Gynecological Cancer Drugs is expected to be a major driver of market growth. Endometrium cancer, a type of cervical cancer, is the most common cancer of the female reproductive organs, according to the American Cancer Society. Furthermore, it is estimated that 47,130 new cases of endometrial cancer will be diagnosed in the United States in 2012, with approximately 8,010 women dying from the disease. 

Furthermore, according to the American Cancer Society, ovarian cancer is the eighth most common cancer among women, and it was estimated in 2012 that approximately 22,280 new cases of ovarian cancer will be diagnosed in the United States, which is expected to support growth in the Gynecological Cancer Drugs

Furthermore, in 2017, the US Food and Drug Administration approved Zejula (niraparib), a targeted therapy drug for women with certain types of the ovarian, fallopian tube, or peritoneal cancer. It is also approved for women who have had a relapse of cancer after undergoing chemotherapy. As of March 2018, the American Cancer Society had funded approximately 22 grants for cervical cancer, totaling approximately US$ 9.3 million. The funding value is offered to a single or group of research projects that include a specific type of cancer or cancer area.

Comments

Popular posts from this blog

Intravenous Fluid Therapy is the Fastest Growing Segment Fueling the Growth of Intravenous Solutions Market

Endometrial Ablation Market Analysis, Industry Scope, Global Opportunity Analysis and Forecast Till 2027

Blowing Agents Market Top Companies, Trends & Growth Factors, and Trend Forecast to 2025